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ABSTRAK
Latar belakang: panduan tatalaksana untuk kolitis ulseratif (KU) belum tersedia. Saat ini, mesalazine, 
kortikosteroid, dan imunomodulator merupakan pilihan terapi untuk KU. Namun, obat-obatan tersebut memiliki 
efek samping yang tidak menyenangkan, misalnya mual, muntah, sakit kepala, hepatitis, dan infertilitas pria. 
Curcumin terdapat dalam tanaman Kunyit (Curcuma longa L.) yang memiliki aktivitas anti-inflamasi dan anti-
oksidan. Artikel ini bertujuan menentukan apakah curcumin sebagai terapi adjuvan dapat menginduksi atau 
memelihara status remisi pada KU. Metode: pencarian terstruktur pada tiga database (Cochrane, PubMed, 
Proquest) menggunakan “Curcumin”, “remisi” dan “kolitis ulseratif” sebagai kata kunci. Kriteria inklusi adalah 
uji klinis acak terkontrol, meta-analisis, atau review sistematis yang meneliti curcumin sebagai terapi adjuvan 
pada pasien KU dewasa. Hasil: dari 49 artikel yang ditemukan, didapatkan 3 uji klinis acak terkontrol setelah 
eksklusi artikel – 2 meneliti efektivitas curcumin dalam menginduksi remisi, dan 1 untuk memelihara remisi pada 
kolitis ulseratif. Curcumin lebih efektif secara signifikan dibandingkan plasebo pada semua uji klinis. Efektivitas 
curcumin dapat dijelaskan oleh aktivitas anti-inflamasi yang dimilikinya, yaitu dengan inhibisi jalur NF-kB. 
Regulasi keseimbangan oksidan/anti-oksidan dapat memodifikasi pelepasan sitokin. Meski demikian, metode yang 
digunakan bervariasi antara uji klinis satu dengan yang lain. Oleh karena itu, sulit untuk membandingkannya 
secara objektif. Selain itu, jumlah sampel yang digunakan juga kecil (n= 50, 45, 89), sehingga tidak terdapat 
kekuatan statistik yang cukup untuk mewakili seluruh populasi pasien kolitis ulseratif dewasa. Kesimpulan: studi 
yang ada menunjukkan bahwa curcumin memiliki potensi untuk menginduksi dan memelihara status remisi pada 
pasien KU tanpa menimbulkan efek samping yang serius. Meski demikian, diperlukan studi lebih lanjut dengan 
jumlah sampel yang lebih besar sebelum curcumin dapat direkomendasikan sebagai terapi adjuvan untuk KU.
Kata kunci: curcumin, kolitis ulseratif, pemeliharaan, remisi.
ABSTRACT
Background: treatment guidelines for ulcerative colitis (UC) not yet established. Currently, mesalazine, 
corticosteroids, and immunomodulators are treatment options for UC. However, they are known to have 
unpleaseant side effects such as nausea, vomiting, headaches, hepatitis, and male infertility. Curcumin is found 
in Turmeric plants (Curcuma longa L.), which possesses both anti-inflammatory and antioxidant properties. 
This study aimed to determine whether curcumin as adjuvant therapy can induce or maintain remission in UC 
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patients. Methods: structured search in three database (Cochrane, PubMed, Proquest) using “Curcumin”, 
“remission” and “Ulcerative Colitis” as keywords. Inclusion criteria is randomized controlled trials (RCTs), 
meta-analysis, or systematic review using curcumin as adjuvant therapy in adult UC patients. Results: we found 
49 articles. After exclusion, three RCTs were reviewed; two examined curcumin efficacy to induce remission 
and one for remision maintenance in UC. Curcumin was significantly more effective than placebo in all RCTs. 
The efficacy of curcumin could be explained by its anti-inflammatory properties, which inhibit NF-kB pathway. 
Regulation of oxidant/anti-oxidant balance can modify the release of cytokines. However, methods varied 
between RCTs. Therefore, they cannot be compared objectively. Futhermore, the sample size were small (n= 
50, 45, 89) therefore the statistical power was not enough to generate representative results in all UC patients. 
Conclusion: Available evidence showed that curcumin has the potential to induce and maintain remission in UC 
patients with no serious side effects. However, further studies with larger sample size are needed to recommend 
it as adjuvant therapy of ulcerative colitis.
Key words: curcumin, remission, maintenance, ulcerative colitis (UC).
INTRODUCTION 
Ulcerative colitis (UC) is an immune-
mediated chronic intestinal condition that causes 
inflammation and ulcers on the large intestine’s 
inner lining. It is one of the two major types 
of inflammatory bowel disease (IBD). The 
incidence of UC varies between geographic 
areas, the highest incidence occurs in Europe, 
United Kingdom, and North America; its 
prevalence ranges from 21.4 – 246 cases per 
100,000 person per year. However, the incidence 
of UC is rising in regions previously thought to 
have low incidence, for example in Hong Kong 
the incidence of UC has increased six-fold in 
the past two decades. UC’s peak age of onset 
is between 15 – 30 years old, and second peak 
occurs between 60 – 80 years old. Mortality 
is the highest during the first years of disease, 
and in long-duration disease due to the risk of 
colon cancer. In a large population study, the 
standardized mortality ratios for UC was 1.1.1  
In addition, UC also produces symptoms that 
impair quality of life and ability in carrying 
work or daily activities.2 Therefore, an effective 
treatment regimen for UC is needed to relieve 
its symptoms and maintain disease remission.
However, treatment guidelines for UC 
has not been established yet. Currently, 
5-aminosalicylates (5-ASA), corticosteroids, 
su l f a sa l az ine  (SZ) ,  mesa laz ine ,  and 
immunomodulators are treatment options for 
patients with active UC. Nonetheless,  they are 
known to have unpleaseant side effects such 
as nausea, vomiting, headaches, hepatitis, and 
male infertility.3-6 Moreover, 20 – 30% patients 
failed to respond to the drugs given for induction 
of remission.7 Hence, new alternatives for UC 
treatment are being sought.
Inappropriate and persistent immune 
response against commensal intestinal bacterial 
flora plays a central role in the pathogenesis of 
UC. There is an enhanced T-cell response to 
the bowel luminal contents accompanied by 
excessive neutrophil influx in colonic tissue, 
leading to uncontrolled inflammation. The role 
of proinflammatory cytokines interleukin (IL)-
1β, IL-6, tumour necrosis factor (TNF)-α, IL-12, 
and interferon (IFN)-γ in initiating and sustaining 
the mucosal inflammation has been established 
in animal models as well as in human studies. 
Nuclear Factor kappa B (NF-κB) is the main 
up-regulator of expression of these cytokines, 
and is strongly activated in UC, suggesting 
important role in its pathogenesis.1,8 Curcumin 
is found in Turmeric plants (Curcuma longa 
L.), which possesses both anti-inflammatory 
and antioxidant properties. Recently, its use for 
treatment of inflammatory diseases, including 
UC, has gained increasing interest for research. 
Therefore, this review is focused on curcumin’s 
efficacy as adjuvant therapy to induce or maintain 
remission in adult UC patients.
METHODS
The search strategy and study selection 
criteria were based on problem-intervention-
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comparison-outcome (PICO) model to answer 
the clinical question, as described in Table 1. 
Since the clinical question type is intervention, 
searching would be focused to find meta-
analysis, systematic review, or clinical trial to 
answer the clinical question.
Data Sources and Search Strategy
We screened Pubmed, Proquest, and 
Cochrane database on June 10th – 17th, 2016 
for data comparing UC standard therapy with 
curcumin and UC standard therapy alone. We 
used “curcumin”, “remission”, and “ulcerative 
colitis” as keywords. Filters were used to 
limit article types, which is “meta-analysis”, 
“systematic review”, “randomized clinical 
trial”, or “clinical trial”. No filter for date of 
publication was used, and the articles found 
were published between 2005 and 2015. The 
keywords and articles found in each search were 
listed in Table 2.
Selection Criteria
Articles included in this review were 
systematic review, meta-analysis, randomized 
clinical trial, or clinical trial comparing UC 
standard therapy with curcumin and UC standard 
therapy alone. Exclusion criteria for this review 
were: articles with observational design, 
studies using patients <18 years old, studies 
using pregnant patients, animal studies, studies 
assessing endpoint other than maintenance or 
induction of disease remission, and studies 
assessing the effects of drug other than the 
combination of curcumin and standard UC 
therapy. Articles written in languages other than 
English or Indonesian were also excluded. The 
literature screening, study selection, and reasons 
for exclusion were described in the flowchart 
(Figure 1). Eligible studies, which conformed 
to the inclusion and exclusion criteria, were 
assessed for their risk of bias. Publication bias 
was graded using the components of evidence-
based medicine (EBM) toolkit recommended by 
the British Medical Journal (BMJ), which consist 
of randomization, allocation concealment, 
blinding of participants, and other sources of 
bias. The characteristics of included studies, 
along with potential sources of bias were 
summarised in Table 3.
RESULTS
From the 49 studies, 46 did not meet the 
inclusion criteria. Three RCTs were finally 
included in the review (Figure 1); two examined 
curcumin efficacy to induce remission and one 
for maintenance in UC. Curcumin as adjuvant 
therapy was signifiantly more effective than 
placebo in all RCTs (Table 3).
Curcumin as Adjuvant to Induce Remission 
in Ulcerative Colitis
Lang et al used patients with active mild to 
moderate UC who did not respond to maximum 
dose of 5-ASA oral and topical therapy; they 
were randomly assigned to groups given 
curcumin capsules (3 g/day) or placebo for 
Table 1. PICO components
Problem Intervention Comparison Outcome
Adult patients (>18 years 
old) with ulcerative colitis, 
both in active and remission 
phase.
Standard UC therapy (e.g 
corticosteroids, mesalazine) 
plus curcumin, administrated 
via rectal or oral route
Standard UC therapy (e.g 
corticosteroids, mesalazine) 
plus placebo
Remission, as measured by 
Ulcerative Colitis Disease 
Activity Index (UCDAI) < 
3 or Colitis Activity Index 
(CAI) <4 
Table 2. Searching strategy in several database
Engines Search Terms Hits
Pubmed (curcumin [MeSH Terms] AND ulcerative colitis [MeSH Terms]) AND 
remission
21
Cochrane “curcumin” AND “ulcerative colitis” AND “remission” 15
Proquest “curcumin” AND “ulcerative colitis” AND “remission” 13
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1 month with continued 5-ASA. This study 
reported 53.8% patients in curcumin group 
experienced remission compared to none in the 
placebo group (odds ratio (OR) 42, 95% CI 2.3 
– 760). Clinical response (i.e. decrease in clinical 
score, but did not fulfill remission criteria) was 
also higher in the curcumin group (65.3% vs 
12.6%, OR 13.2, 95% CI 3.1 – 56.6).9
Singla et al8 used patients with active 
mild to moderate UC in distal colon (<25 cm 
disease involvement from anal verge) who 
were already on oral mesalamine for at least 8 
weeks. They were randomly assigned to groups 
given curcumin enema (NCB-02) plus oral 
5-ASA or placebo enema plus oral 5-ASA once 
daily. This study reported 43.4% remission in 
curcumin group compared to 22.7% in placebo 
group. Clinical response was also higher in the 
curcumin group (56.5% vs. 36.4%). Number 
needed to treat in both studies were small, less 
than 50 patients.
Curcumin as Adjuvant to Maintain Remission 
in Ulcerative Colitis
Hanai et al10 used patients with quiescent UC 
and randomly assigned to oral curcumin (2 g/
day) plus sulfasalzine or mesalamine (depending 
on which drug the patients already used before 
trial), or placebo capsules plus sulfasalazine 
or mesalamine (depending on which drug the 
patients already used before trial). Patients 
experienced recurrence were fewer in curcumin 
group both at 6-month follow-up (10% vs. 14%) 
and 12-month follow-up (22.2% vs 31.8%).10 
Number needed to treat was small, less than 50 
patients.
DISCUSSION
In all studies that we found, curcumin was 
significantly more effective as adjuvant therapy 
to induce or maintain UC remission, compared 
to placebo.8-10 A small number needed to treat 
showed that curcumin had significant benefit 
for patients and could potentially be used in 
Figure 1. Flow chart of search strategy
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day + + + - + + + + 22.7 43.5 91.6 20.8 5 (3–17 )
Hanai 
(2006)10 89 + Oral, 2g/day + + + + + + + + 68.2 77.8 14.1 9.6 11 (4–12)
P:patient, I: intervention, C: comparison, +: placebo. O: outcome, +: remission. In validity, +: yes, -: no. CER: control event 
rate, event=outcome. EER: experimental event rate, event=outcome. RRR: relative risk reduction, minus (-):RRR cannot 
be counted because the CER is 0 (zero) percent. ARR: absolute risk reduction. NNT: number needed to treat.  
CI : confidence interval
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clinical settings. This effect might be explained 
by curcumin’s anti-inflammatory properties. 
Inhibition of NF-κB was postulated as its main 
anti-inflammatory properties. The mechanism of 
action involves inhibition of IKK (IκB kinase) 
which leads to inhibition of both cytokine 
mediated phosphorylation and degradation of 
IκB, which is an inhibitor of NF-κB. As a result 
of NF-κB inhibition, IL-2 synthesis, as well as 
IL-2 and mitogen activation of human leukocytes 
are also inhibitied. Curcumin is also indicated to 
have inhibiting effect on tumor necrosis factor α 
(TNF-α) and phorbol ester-induced binding of 
NF-κB transcription factors to sites located on 
the GSTP-1 (glutathione S-transferase P1-1) gene 
promoter – therefore, it could induce apoptosis by 
inhibiting GSTP-1 expression at the transcription 
level. In animal studies, curcumin also showed 
ability to suppresss CD4+ T-cell infiltration, 
thereby reducing the inflammatory response.8-11
Adverse events were not significantly 
different in the placebo and curcumin groups in 
all trials.8-10 The most common side effects of 
curcumin was gastrointestinal complaint, such 
as nausea and sensation of abdominal distension; 
it was usually mild, transient and no subjects in 
the studies dropped out because of curcumin’s 
side effects.10 This side effects could be reduced 
by administering curcumin via rectal route 
(enema), especially for patients with distal UC. 
Futhermore, topical preparation can bypass first 
pass metabolism in the liver, which is high for 
oral preparation of curcumin.8 The good safety 
profile of curcumin places it as a promising agent 
in UC treatment. Moreover, not only curcumin 
could improve clinical symptoms, it could also 
improve endoscopic findings of the colon, as 
described by Lang, et al.9 In animal models of 
colon cancer, curcumin was reported to inhibit 
dysplasia and neoplasia. This chemopreventive 
activities might be mediated by inhibition of 
cyclo-oxygenase-2 expression.8 Curcumin also 
strongly inhibited proliferation of HT-29 and 
HCT-15 human colon cancer cell lines. Therefore 
long treatment with curcumin might also inhibit 
colorectal cancer development in UC patients, 
which needed to be studied further.11 However, 
all studies we found used a relatively small 
sample size (50,45, and 89), and one trial only 
conducted one month follow-up – the  statistical 
power is not enough to generate representative 
results in all UC patients. Moreover, the studies 
each used different curcumin dosage and routes 
of administration, and different follow-up 
period; it could not be objectively compared. 
Futhermore, clinical scoring system used in 
each trial was slightly different from each other. 
As a result, the quantitative data from those 
trials could not be integrated to form a pooled 
analysis. We concluded that further studies with 
larger sample size are needed to recommend it 
as adjuvant therapy of ulcerative colitis.
Additionally, studies comparing the 
effectivity of various combination of curcumin 
and standard UC therapy were also needed, e.g 
curcumin-mesalamine, curcumin-steroids, etc. 
Similar to curcumin, mesalamine also acts by 
inhibiting NF-κB pathway. The combination of 
curcumin and mesalamine had shown increased 
efficacy compared to mesalamine therapy 
alone. This might be due to synergistic action 
of curcumin with mesalamine, or inhibition of 
other inflammatory pathways by curcumin.8 
Comparison of synergistic effect between 
curcumin and various drugs used in UC therapy 
has not been established. Furthermore, studies 
comparing various curcumin dosage (e.g 2 g/day, 
3 g/day, etc). were needed to obtain curcumin 
dosage and avoid gastrointestinal side effects 
caused by unneccessarily high curcumin dosage. 
Recently, various formulation of oral curcumin 
is also developed to increase its absorption rate, 
because curcumin is a poorly water-soluble 
drug. Li et al12 used curcumin and piperine (PIP) 
co-encapsulated into the nanoformulation called 
self-microemulsifying drug delivery system 
(SMEDDS) to improve the stability and water-
solubility of curcumin and enhance its anticolitis 
activity. Lately, oral colon-specific drug delivery 
has been developed, using microparticles as drug 
carrier to achieve controlled drug-release in the 
colon. Curcumin-loaded microparticles has been 
used in animal and in-vivo studies, and showed 
promising results.13 These methods might hold 
promis for more efficient clinical treatment of UC. 
Therefore, studies comparing curcumin efficacy 
between different routes and formulation were 
also needed.
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CONCLUSION
Available evidence showed that adjuvant 
therapy using curcumin has potential to induce 
and maintain remission in UC patients with no 
serious side effects. However, further studies 
with larger sample size are needed to recommend 
it as adjuvant therapy of ulcerative colitis.
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